Drug application
NAPROXEN (NAPROXEN)
Drugs@FDA ANDA 212517 · SCIEGEN PHARMS
Key facts
| Drug name | NAPROXEN |
|---|---|
| Active ingredients | NAPROXEN |
| Application type | ANDA |
| Application number | 212517 |
| Company | SCIEGEN PHARMS |
| Dosage forms | TABLET, ORAL |
| Strength | 250MG |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Feb 21, 2020 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- 10–99 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.